Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...
From his time in the industry before the contemporary good manufacturing practice (cGMP), senior drug substance consultant at DSI, a ProductLife Group company, Dave Adams quickly grasped the necessity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results